Clinical

Dataset Information

0

A clinical study of TG6002 and flucytosine in patients with gastro-intestinal tumors


ABSTRACT: Primary objectives: Phase I: determination of the recommended phase II dose Phase IIa: efficacy of multiple administrations of TG6002 in combination with flucytosine (or Ancotil or 5-FC) Primary endpoints: Phase I: adverse events, serious adverse events, change in standard laboratory parameters and vital signs, dose-limiting toxicities. Phase IIa: overall response rate.

DISEASE(S): Gastro-intestinal Cancer,Gastrointestinal Cancer Metastatic,Cancer Gastro-intestinal

PROVIDER: 2537744 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2538646 | ecrin-mdr-crc
| 2288207 | ecrin-mdr-crc
| 2531813 | ecrin-mdr-crc
| 2538990 | ecrin-mdr-crc
2023-08-30 | MSV000092799 | MassIVE
| 2324305 | ecrin-mdr-crc
2024-10-04 | GSE278391 | GEO
2023-12-15 | GSE249542 | GEO
2023-12-15 | GSE249023 | GEO
| EGAS00001006172 | EGA